PCRX

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.04
Percentage change -0.17	%

Peers: INCY EXEL ACAD RDUS ENTA CORT ANAB LGND AMLX PBYI

| Held by: IJR VTI VB IWM AVUV VXF VBR IJS SPSM IWN

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.29	Insider Own	4.43%	Shs Outstand	46.28M	Perf Week	-2.93%
Market Cap	1.07B	Forward P/E	6.78	EPS next Y	3.43	Insider Trans	-1.01%	Shs Float	44.25M	Perf Month	-11.55%
Enterprise Value	1.22B	PEG	-	EPS next Q	0.69	Inst Own	111.22%	Short Float	12.65%	Perf Quarter	-3.57%
Income	-103.73M	P/S	1.53	EPS this Y	-11.38%	Inst Trans	1.19%	Short Ratio	6.83	Perf Half Y	18.12%
Sales	702.77M	P/B	1.35	EPS next Y	20.81%	ROA	-6.54%	Short Interest	5.60M	Perf YTD	23.20%
Book/sh	17.25	P/C	2.18	EPS next 5Y	11.67%	ROE	-12.27%	52W High	28.63 -18.93%	Perf Year	-18.87%
Cash/sh	10.66	P/FCF	6.74	EPS past 3/5Y	- -51.99%	ROIC	-8.48%	52W Low	11.16 107.90%	Perf 3Y	-59.43%
Dividend Est.	-	EV/EBITDA	7.29	Sales past 3/5Y	8.98% 10.73%	Gross Margin	69.46%	Volatility	3.67% 3.42%	Perf 5Y	-48.72%
Dividend TTM	-	EV/Sales	1.73	EPS Y/Y TTM	-247.82%	Oper. Margin	12.16%	ATR (14)	0.86	Perf 10Y	-68.92%
Dividend Ex-Date	-	Quick Ratio	1.99	Sales Y/Y TTM	3.08%	Profit Margin	-14.76%	RSI (14)	35.27	Recom	2.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.41	EPS Q/Q	-46.09%	SMA20	-5.45%	Beta	0.49	Target Price	36.17
Payout	-	Debt/Eq	0.80	Sales Q/Q	1.08%	SMA50	-8.24%	Rel Volume	0.71	Prev Close	23.25
Employees	790	LT Debt/Eq	0.53	Earnings	May 08 AMC	SMA200	6.94%	Avg Volume	820.10K	Price	23.21
IPO	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.94% -4.04%	Trades		Volume	584,349	Change	-0.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Upgrade	Truist	Sell → Hold	$8 → $25
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform	$72 → $75
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$75
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform	$58 → $67

Show Previous Ratings

Jun-18-25 11:06AM	Is the Options Market Predicting a Spike in Pacira BioSciences Stock? (Zacks)
08:00AM	Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 (GlobeNewswire)
Jun-11-25 08:00AM	Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Jun-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 02:02PM	PharmaCorp Rx Inc. Reports First Quarter 2025 Results and Announces Non-Binding Letters of Intent to Acquire Four Pharmacies (GlobeNewswire)
08:00AM	Loading…
May-15-25 08:00AM	Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
May-14-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 10:35AM	Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation (PR Newswire) -6.74%
May-09-25 11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
03:41AM	Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... (GuruFocus.com)
May-08-25 05:30PM	Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Pacira (PCRX) Q1 Earnings Surpass Estimates (Zacks)
04:11PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:20PM	Pacira BioSciences Q1 2025 Earnings Preview (Seeking Alpha)
10:20AM	Loading…
10:20AM	Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 08:00AM	Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis (GlobeNewswire)
May-01-25 05:10PM	Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates (Zacks)
10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
08:32AM	Pharmacorp Completes Acquisition of Pre-1954 Charter Company in Ontario (GlobeNewswire)
Apr-29-25 10:01AM	Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 (GlobeNewswire)
Apr-28-25 08:00AM	Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire) +5.52%
Apr-22-25 04:01PM	Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire)
Apr-21-25 12:10PM	Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again (Zacks) +5.07%
08:15AM	DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders (PR Newswire)
05:00PM	Loading…
Apr-17-25 05:00PM	Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders (GlobeNewswire)
Apr-15-25 01:45PM	Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
Apr-11-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -8.32%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks)
10:03AM	Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act (Seeking Alpha)
09:41AM	Pacira price target raised to $28 from $25 at Truist (TipRanks)
05:53AM	Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-25 11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks) +14.67%
Apr-07-25 04:30PM	Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks)
09:37AM	PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study (Zacks)
Apr-03-25 08:00AM	Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 12:39PM	Pacira Surges 66.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-14-25 04:05PM	Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual (GlobeNewswire)
08:25AM	DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences (PR Newswire)
Mar-06-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-25 07:00AM	Bull of the Day: Pacira BioSciences (PCRX) (Zacks)
Mar-02-25 12:27PM	Is Pacira BioSciences, Inc. (PCRX) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 10:09AM	Q4 2024 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.24%
02:36AM	Pacira BioSciences Inc (PCRX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-27-25 05:26PM	Pacira: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
04:00PM	Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio (GlobeNewswire)
Feb-26-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March (GlobeNewswire)
07:46AM	What To Expect From Pacira BioSciences Inc (PCRX) Q4 2024 Earnings (GuruFocus.com)
Feb-20-25 09:50AM	Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term (Zacks)
08:00AM	Pacira to Report 2024 Financial Results on Thursday February 27, 2025 (GlobeNewswire)
Feb-14-25 05:45AM	Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX (PR Newswire)
Feb-06-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 09:55AM	Should You Buy Pacira (PCRX) After Golden Cross? (Zacks)
Jan-31-25 05:45AM	Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX (PR Newswire)
Jan-30-25 08:00AM	Pacira Announces Updates to Board of Directors (GlobeNewswire)
Jan-21-25 08:00AM	Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments (GlobeNewswire)
Jan-16-25 01:56PM	Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights PCRX (GlobeNewswire)
Jan-10-25 08:00AM	Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization (GlobeNewswire) +11.09%
Jan-07-25 11:49AM	Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain (Benzinga)
08:00AM	Pacira BioSciences Receives FDA 510k Clearance for New iovera SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block (GlobeNewswire)
Jan-02-25 04:01PM	Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 09:50AM	Here's Why Pacira (PCRX) is a Strong Momentum Stock (Zacks)
Dec-11-24 08:05AM	DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc. (PR Newswire)
Dec-06-24 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-03-24 07:30AM	Pacira Awarded New U.S. Patent Covering EXPAREL Composition (GlobeNewswire) -6.34%
Nov-29-24 09:50AM	Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-14-24 10:05AM	Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
Nov-12-24 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
Nov-07-24 08:49AM	Q3 2024 Pacira Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:20AM	Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Nov-06-24 04:10PM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 07:55AM	Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.05%
Nov-04-24 08:00AM	Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings (GlobeNewswire)
Oct-30-24 08:00AM	Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 (GlobeNewswire)
Oct-21-24 08:38AM	Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock? (Zacks)
08:00AM	Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer (GlobeNewswire)
Oct-07-24 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Oct-03-24 08:00AM	Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 (GlobeNewswire)
Sep-26-24 08:00AM	Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
Sep-25-24 08:15AM	DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders (PR Newswire)
Sep-09-24 04:00PM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-09-24 03:21PM	Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey (GlobeNewswire) -47.67%
Jul-31-24 10:49AM	Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues (Zacks) +5.68%
Jul-30-24 08:58PM	PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
04:14PM	Pacira: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-29-24 06:00AM	3 Biotech Stocks to Buy on the Dip: July 2024 (InvestorPlace)
Jul-23-24 08:00AM	Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024 (GlobeNewswire)

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIKER LAUREN	Senior Vice President, Finance	Jun 04 '25	Sale	26.21	5,578	146,208	59,564	Jun 05 05:40 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '25	Sale	26.24	14,376	377,226	161,574	Jun 05 05:37 PM
RIKER LAUREN	Officer	Jun 04 '25	Proposed Sale	26.21	5,579	146,209		Jun 04 11:36 AM
WILLIAMS KRISTEN	Officer	Jun 04 '25	Proposed Sale	26.24	14,376	377,226		Jun 04 10:37 AM
GAUGLER DARYL	Officer	Mar 06 '25	Proposed Sale	23.25	500	11,625		Mar 06 12:06 PM
SLONIN JONATHAN	Chief Medical Officer	Jan 06 '25	Sale	18.40	879	16,174	93,444	Jan 06 06:23 PM
SLONIN JONATHAN	Officer	Jan 06 '25	Proposed Sale	18.40	879	16,174		Jan 06 11:11 AM
GAUGLER DARYL	Chief Operating Officer	Dec 13 '24	Sale	19.76	500	9,880	115,200	Dec 16 04:13 PM
GAUGLER DARYL	Officer	Dec 13 '24	Proposed Sale	19.76	500	9,880		Dec 13 09:41 AM
GAUGLER DARYL	Chief Operating Officer	Sep 13 '24	Sale	12.86	500	6,430	115,700	Sep 13 08:29 PM
GAUGLER DARYL	Officer	Sep 13 '24	Proposed Sale	12.86	500	6,430		Sep 13 10:17 AM
BIGAL MARCELO	Director	Aug 16 '24	Buy	13.25	1,512	20,034	10,142	Aug 19 08:25 AM
Brege Laura	Director	Aug 16 '24	Buy	12.81	1,000	12,810	17,552	Aug 19 08:25 AM
YANG MICHAEL J.	Director	Aug 14 '24	Buy	12.90	2,000	25,800	7,230	Aug 14 04:35 PM
Lee Frank D.	Chief Executive Officer	Aug 12 '24	Buy	12.10	8,264	99,994	107,784	Aug 13 04:55 PM
Froimson Mark	Director	Aug 12 '24	Buy	11.58	1,400	16,212	14,473	Aug 12 08:33 PM
BIGAL MARCELO	Director	Aug 12 '24	Buy	12.01	3,400	40,834	8,630	Aug 12 08:33 PM
SLONIN JONATHAN	Chief Medical Officer	Aug 02 '24	Sale	20.05	945	18,947	94,307	Aug 02 06:00 PM
SLONIN JONATHAN	Officer	Aug 02 '24	Proposed Sale	20.05	945	18,947		Aug 02 10:09 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Pacira BioSciences Inc

Upgrade your FINVIZ experience